The U. S. Food and Drug Administration last spring linked contaminated batches of the animal-based product, imported from China, to more than 80 deaths and hundreds of allergic reactions among patients exposed to the drug for kidney dialysis and other conditions.
Described here today at the ACS's 236th National Meeting, the purer, non-animal version could improve the drug's safety and bolster regulatory control of its manufacture, the researchers say. Scientists expect demand for heparin, which prevents blood clots, to increase in the future due to rising rates of diabetes, heart disease, and other health complications linked to sedentary lifestyles. Global heparin sales total about $4 billion annually.
"With the problems associated with contaminated heparin produced from pig tissues in China, a non-animal source of this essential drug is gaining importance," says study co-author Robert J. Linhardt, Ph.D., a chemist with Rensselaer Polytechnic Institute in Troy, New York. "A safer version of the drug could result in less adverse effects and fewer deaths."
Heparin can be given by injection to prevent life-threatening blood clots during heart surgery and kidney dialysis. It also is used to clean intravenous lines used in those procedures. Because heparin is difficult to make in the lab from scratch, the drug's only source has been from pig intestines.
Linhardt points out that processing of pig intestines to extract the raw materials is often done in small, family-run workshops in China, which supplies about 70 percent of the world's heparin. Those mom-and-pop shops often fall outside the normal supervision and regulatory control standard in the pharmaceutical industry. The lack of oversight increases the risks of heparin contamination or adulteration with harmful chemicals, viruses, or other agents, he says.
"If heparin is prepared the right way, it should be consistent and safe, even from an animal source," says Linhardt, who was part of the team that identified the suspected chemical contaminant in the Chinese heparin. The contaminant, called oversulfated chondroitin sulfate, can cause life-threatening allergic reactions. Heparin supplies containing the contaminant have now been recalled.
Researchers have been trying for years to develop heparin production methods that don't require pig intestines. The first so-called total synthesis of heparin, developed in 2003 at the Massachusetts Institute of Technology (MIT), was not practical. It produced only minute batches of heparin — less than 0.000000035 ounces at a time — and could not be scaled up for commercial use, Linhardt says.
Working with Jian Liu, Ph.D., a medicinal chemist with the University of North Carolina-Chapel Hill, and Jonathan Dordick, Ph.D., a Rensselaer chemical engineer, Linhardt's team now has developed an alternative synthesis method that boosts heparin production a million times higher than the MIT technique. The scientists employed a patented biotechnology approach that uses powerful enzymes to string together the individual carbohydrate units that form the pure heparin polymer. "Our biotech version of heparin will be prepared in a controlled environment ensuring that it is pure and free of contaminants," Linhardt says.
So far, only small amounts of the new heparin have been produced in the laboratory using this technique, called "chemoenzymatic synthesis." But Linhardt reports that the new approach can be used to produce the drug on a larger scale suitable for industrial manufacture. Cost, dosing, and administration of the new drug should be the same as conventional, animal-based heparin, he notes.
Linhardt plans to begin testing the synthetic heparin on animals this summer. If these and other tests are successful, the new heparin could reach the consumer market in two to five years, he estimates. The National Institutes of Health provided primary funding for the project.
Charmayne Marsh | EurekAlert!
Multi-institutional collaboration uncovers how molecular machines assemble
02.12.2016 | Salk Institute
Fertilized egg cells trigger and monitor loss of sperm’s epigenetic memory
02.12.2016 | IMBA - Institut für Molekulare Biotechnologie der Österreichischen Akademie der Wissenschaften GmbH
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water
In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...
The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.
Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
02.12.2016 | Medical Engineering
02.12.2016 | Agricultural and Forestry Science
02.12.2016 | Physics and Astronomy